Arvinas (ARVN) Short term Debt (2017 - 2023)

Arvinas (ARVN) posted quarterly Short term Debt of $200000.0 for Q3 2023, up 100.0% quarter-over-quarter from $100000.0 in Q2 2023.

Arvinas (ARVN) Short term Debt (2017 - 2023) Analysis & Trends

Arvinas' Short term Debt history runs 4 years deep, the most recent figure standing at $200000.0 for Q3 2023.

In Q3 2023, Short term Debt changed N/A year-over-year to $200000.0; the TTM figure through Sep 2023 stood at $200000.0 (changed N/A YoY), while the FY2018 annual figure was $154461.0, down 3.02% from the prior year.
Short term Debt for Q3 2023 stood at $200000.0, up from $100000.0 in the prior quarter.
The five-year high for Short term Debt was $200000.0 in Q3 2023, with the low at $71499.0 in Q2 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Arvinas	585.74 Mn	17.84 Mn	-

Download Data